(5)

research, development and innovation, in particular through: research and innovation projects that contribute to the objectives of Horizon Europe, including research infrastructure and support to academia; corporate projects, including training and promoting the creation of clusters and business networks; demonstration projects and programmes, as well as deployment of related infrastructures, technologies and processes; collaborative research and innovation projects involving academia, research and innovation organisations and industry; public-private partnerships and civil society organisations; knowledge and technology transfer; research in the field of key enabling technologies (KETs) and their industrial applications, including new and advanced materials; and new effective and accessible healthcare products, including research, development, innovation and manufacturing of pharmaceuticals, medical devices, diagnostics and advanced therapy medicinal products and new antimicrobials, as well as innovative development processes that avoid using animal testing.

← anx_II__point_4__text_1 · All articles · anx_II__point_5__text_1 →

Source: EUR-Lex (Cellar) · retrieved 2026-10-30 · Text as adopted (Official Journal); later amendments are not incorporated in this text.